Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
- 1 August 2015
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 42 (4), 601-616
- https://doi.org/10.1053/j.seminoncol.2015.05.007
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (1K08CA160692-01A1, U54CA163125-01)
This publication has 128 references indexed in Scilit:
- Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor modelsCancer Immunology, Immunotherapy, 2013
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor ImmunityPLOS ONE, 2013
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007